Seres Therapeutics

Seres Therapeutics announced FDA Breakthrough Therapy designation for SER-155, reducing bloodstream infections in allogeneic hematopoietic stem cell transplant patients. SER-155 showed significant reductions in bloodstream infections, systemic antibiotic exposure, and febrile neutropenia, with no serious adverse events. The designation supports efficient drug development and a potential commercial opportunity in allo-HSCT.

FDA grants Breakthrough Therapy designation to Seres Therapeutics' SER-155 for reducing bloodstream infections in allo-HSCT patients, based on Phase 1b data showing 77% relative risk reduction. Seres plans to meet with FDA in Q1 2025 to discuss next study and seeks strategic partnership for SER-155.

Seres Therapeutics announced FDA Breakthrough Therapy designation for SER-155, designed to reduce bloodstream infections in allo-HSCT patients, following a Phase 1b study showing a 77% risk reduction. The company seeks partnerships to expedite SER-155's development and expand its use, aiming to improve patient outcomes in vulnerable populations.

FDA grants Seres Therapeutics Breakthrough Therapy designation to SER-155 for reducing bloodstream infections in allo-HSCT patients, based on Phase 1b data showing 77% relative risk reduction. Seres plans FDA meeting in Q1 2025 and seeks strategic partnership for SER-155.

Seres Therapeutics reported $0 revenue, $(29.17) million loss from operations, and $88.78 million net income in Q3 2024, primarily due to the sale of VOWST Business. The company is advancing SER-155, a live biotherapeutic for allo-HSCT patients, with plans to evaluate it in other vulnerable populations. Seres faces challenges including funding needs, regulatory approval risks, and competition.

David Arkowitz, former CFO of Seres Therapeutics and other biotech companies, joins Alkeus Pharmaceuticals as CFO. He has over 30 years of experience in finance, operations, and business development. Arkowitz is excited to contribute to Alkeus' mission of developing an oral therapy for Stargardt disease.

Despite 16 new antibacterial drugs approved since 2017 and 97 more in development, superbugs continue to evolve faster than treatments can be developed. Organizations like CARB-X are funding unconventional approaches, including phage therapy and synthetic antimicrobials, to combat antimicrobial resistance. However, the lack of private investment and slow legislative action hinder progress, emphasizing the urgent need for increased funding and recognition of the threat posed by superbugs.

Tulisokibart maintained clinical and endoscopic improvements in IBD patients through week 50 in phase II trial extensions, with 48% of ulcerative colitis patients and 56% of Crohn's disease patients achieving clinical remission. The drug was well-tolerated with no identified safety signals.

The gut microbiome's role in neurological diseases is increasingly recognized, with potential implications for treatment and diagnosis. Research highlights connections between gut health and conditions like Parkinson’s, ALS, ADHD, and autism, though rigorous validation is still needed. Emerging therapies aim to modulate the gut microbiome to mitigate symptoms, with ongoing trials showing promise.